MedTrace Logo

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

NCT03104439 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2026-01-12

No results posted yet for this study

Summary

This research study is studying a combination of drugs with radiation therapy as a possible treatment for Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, or MSI High Colorectal Cancer.

The interventions involved in this study are:

* Nivolumab
* Ipilimumab
* Radiation Therapy

Conditions

  • Microsatellite Stable Colorectal Cancer
  • Pancreatic Cancer
  • MSI High Colorectal Cancer

Interventions

DRUG

Nivolumab

The antibodies in nivolumab work by causing programmed cell death of the cancer cells

DRUG

Ipilimumab

The antibodies in ipilimumab work by not allowing cancer cell growth

RADIATION

Radiation Therapy

Radiation therapy is believed to increase the likelihood of response of immunotherapy

Sponsors & Collaborators

Principal Investigators

  • Julie Koenig, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-10
Primary Completion
2027-01-31
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03104439 on ClinicalTrials.gov